tiprankstipranks
Immunome price target lowered to $8 from $9 at Chardan
The Fly

Immunome price target lowered to $8 from $9 at Chardan

Chardan analyst Matthew Barcus lowered the firm’s price target on Immunome (IMNM) to $8 from $9 but keeps a Buy rating on the shares. The company’s collaboration and option agreement with AbbVie (ABBV) not only provides external validation of the company’s discovery platform, but also provides important non-dilutive financing for the company, which ended 2022 with $20.3M in cash and cash equivalents, the analyst tells investors in a research note.

Published first on TheFly

See the top stocks recommended by analysts >>

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles